Looking Back on 2018: Our 10 Most Popular Interviews
As 2018 draws to a close and our thoughts are torn between holiday plans and…
24/12/2018 - 8 minutes
CAR-T
CAR-T Promise for Patients with Solid Tumors
A new CAR-T cancer therapy from the Belgian company Celyad has shown early positive results…
14/11/2018 - 3 minutes
Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe
Update: Following on from earlier approvals in the US, the European Commission announced it has given…
28/08/2018 - 4 minutes
Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease
Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent…
23/07/2018 - 3 minutes
Kite Partners with Dutch Biotech to Develop a New Form of CAR-T Therapy
Kite will support Gadeta in the development of a new type of CAR-T therapy that…
19/07/2018 - 3 minutes
Next-Generation CAR-T Company Raises €130M on NASDAQ IPO
London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a…
22/06/2018 - 2 minutes
French Biotech Develops a New Generation of Safer CAR-T Cells
Cellectis is developing a new type of chimeric antigen receptor that could improve the production…
13/06/2018 - 2 minutes
CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead
CAR-T cell therapy has been able to effectively treat cancer in some patients for whom…
13/06/2018 - 5 minutes
Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race
Update (23/05/2018): Investors have fully subscribed Celyad's global offering of shares on NASDAQ and Euronext…
23/05/2018 - 2 minutes
Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV
TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation…
08/05/2018 - 2 minutes
Novartis and Gilead’s CAR-T Therapies Now Compete for the Same Cancer Patients
The FDA has approved the use of Novartis' CAR-T therapy Kymriah in adult patients with…
02/05/2018 - 2 minutes
The First CAR-T Therapy Is Not Living Up to Commercial Expectations
Novartis' Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in…
23/04/2018 - 3 minutes
